-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Lucy Scientific Discovery (LSDI) Surges Pre-Market, Driven by Short Squeeze
Lucy Scientific Discovery (LSDI) Surges Pre-Market, Driven by Short Squeeze
Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a psychedelic products company, is experiencing a tremendous pre-market price surge of 62%, adding to the positive momentum of the day which already saw a 15% increase.
The market's heightened interest in LSDI reflects the growing fascination with psychedelic research and its potential impact on the biopharmaceutical industry.
LSDI's Remarkable Short Squeeze
Lucy Scientific Discovery Inc. (LSDI), a relatively new player in the market, has been on a volatile ride since its debut less than four months ago. However, the company is currently experiencing a significant pre-market price jump, reaching $1.73 per share, marking its highest level since March.
This sudden surge is being attributed to a short squeeze among traders, indicating that bears with short positions on LSDI stock are now rushing to cover their positions, resulting in increased demand and upward pressure on the stock price. The market is closely watching this development, anticipating further momentum for LSDI.
Lucy Scientific and TheraPsil Join Forces
In a significant development, Lucy Scientific Discovery Inc. (LSDI) has announced a partnership with TheraPsil, a leading non-profit organization advocating for legal access to psilocybin therapy in Canada.
This collaboration aims to advance medical psilocybin access and research, specifically targeting patients in need of end-of-life care and those with serious medical conditions.
The partnership not only facilitates patient access and supports compassionate care but also allows Lucy to introduce natural psilocybin products into the Canadian market, positioning the company as a pioneer in psychedelic compounds. This strategic move not only offers early consumer feedback but also strengthens Lucy's brand recognition in Canada and beyond.
Conclusion
LSDI stock has witnessed an impressive pre-market price surge, attributed to a short squeeze and fueled by growing interest in psychedelic research. The company's partnership with TheraPsil further solidifies its position in the industry, enabling access to psilocybin therapy and paving the way for the introduction of natural psilocybin products.
Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a psychedelic products company, is experiencing a tremendous pre-market price surge of 62%, adding to the positive momentum of the day which already saw a 15% increase.
迷幻产品公司Lucy Scientific Discovery Inc.(纳斯达克股票代码:LSDI)的盘前价格大幅上涨了62%,这加剧了当天已经上涨15%的积极势头。
The market's heightened interest in LSDI reflects the growing fascination with psychedelic research and its potential impact on the biopharmaceutical industry.
市场对LSDI的兴趣日益浓厚,这反映了人们对迷幻研究及其对生物制药行业的潜在影响的迷恋与日俱增。
LSDI's Remarkable Short Squeeze
LSDI 的惊人空头挤压
Lucy Scientific Discovery Inc. (LSDI), a relatively new player in the market, has been on a volatile ride since its debut less than four months ago. However, the company is currently experiencing a significant pre-market price jump, reaching $1.73 per share, marking its highest level since March.
Lucy Scientific Discovery Inc.(LSDI)是市场上相对较新的参与者,自不到四个月前首次亮相以来,一直处于动荡之中。但是,该公司目前正在经历盘前价格的大幅上涨,达到每股1.73美元,这是自3月份以来的最高水平。
This sudden surge is being attributed to a short squeeze among traders, indicating that bears with short positions on LSDI stock are now rushing to cover their positions, resulting in increased demand and upward pressure on the stock price. The market is closely watching this development, anticipating further momentum for LSDI.
这种突然的飙升归因于交易者的空头挤压,这表明在LSDI股票上空头寸的空头现在正急于填补头寸,导致需求增加和股价面临上行压力。市场正在密切关注这一事态发展,预计LSDI将进一步发展势头。
Lucy Scientific and TheraPsil Join Forces
露西科学和TherapSil联手
In a significant development, Lucy Scientific Discovery Inc. (LSDI) has announced a partnership with TheraPsil, a leading non-profit organization advocating for legal access to psilocybin therapy in Canada.
Lucy Scientific Discovery Inc.(LSDI)宣布与TherapSil建立合作伙伴关系,TherapSil是一家倡导在加拿大合法获得psilocybin疗法的领先非营利组织,这是一个重大进展。
This collaboration aims to advance medical psilocybin access and research, specifically targeting patients in need of end-of-life care and those with serious medical conditions.
这项合作旨在促进医用 psilocybin 的普及和研究,特别针对需要临终护理和患有严重疾病的患者。
The partnership not only facilitates patient access and supports compassionate care but also allows Lucy to introduce natural psilocybin products into the Canadian market, positioning the company as a pioneer in psychedelic compounds. This strategic move not only offers early consumer feedback but also strengthens Lucy's brand recognition in Canada and beyond.
该合作伙伴关系不仅为患者提供便利,支持富有同情心的护理,而且还使露西能够将天然psilocybin产品引入加拿大市场,使该公司成为迷幻化合物的先驱。这一战略举措不仅提供了早期的消费者反馈,还增强了露西在加拿大及其他地区的品牌知名度。
Conclusion
结论
LSDI stock has witnessed an impressive pre-market price surge, attributed to a short squeeze and fueled by growing interest in psychedelic research. The company's partnership with TheraPsil further solidifies its position in the industry, enabling access to psilocybin therapy and paving the way for the introduction of natural psilocybin products.
LSDI股票见证了令人印象深刻的盘前价格飙升,这归因于空头挤压,并受对迷幻研究的兴趣与日俱增。该公司与TherapSil的合作进一步巩固了其在行业中的地位,使人们能够获得psilocybin疗法,并为引入天然psilocybin产品铺平了道路。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧